#78 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians should be aware that cannabis vaping may increase the risk of cannabinoid hyperemesis syndrome (CHS), a condition characterized by severe cyclic vomiting that can be debilitating and difficult to diagnose. Patients who present with unexplained nausea and vomiting should be systematically queried about cannabis use, particularly vaping methods, as this symptom pattern may improve with cannabis cessation rather than standard antiemetic treatments. This evidence helps clinicians differentiate CHS from other causes of recurrent vomiting and allows for appropriate patient counseling regarding the hyperemetic risks associated with cannabis consumption methods.
A new study published in Cannabis and Cannabinoid Research identifies a clinical association between cannabis vaping and cannabinoid hyperemesis syndrome (CHS), a condition characterized by severe, cyclic vomiting that can significantly impair patient quality of life. The research adds to existing evidence linking cannabinoid use to CHS, though the specific mechanisms remain incompletely understood and may relate to dose, frequency, potency, or individual susceptibility factors. This finding is particularly relevant given the rising prevalence of high-potency vaping products in the market, which deliver concentrated cannabinoids and may pose greater CHS risk than traditional cannabis preparations. Clinicians should maintain awareness of CHS as a potential diagnosis in patients presenting with intractable nausea and vomiting, particularly those reporting regular cannabis use, and should counsel patients about this risk during the informed consent discussion before recommending cannabis therapy. Patients who develop recurrent vomiting associated with cannabis use should be advised that cessation remains the only definitively effective treatment, though symptom management with antiemetics and hydration may provide interim relief. Clinicians should screen patients for CHS symptoms and discuss this emerging adverse effect when evaluating cannabis use in symptomatic patients to enable shared decision-making.
“Cannabinoid hyperemesis syndrome is real and I see it regularly in my practice, typically in heavy daily users who vape high-potency products, and the key clinical point that gets missed is that stopping cannabis completely is the only effective treatment—no antiemetic works until they abstain.”
🤢 Cannabinoid hyperemesis syndrome represents a paradoxical clinical entity wherein regular, high-potency cannabis use—particularly through vaping—precipitates severe, cyclic vomiting that often resolves only with cannabis cessation. While the underlying mechanism remains incompletely understood, emerging evidence suggests a dose-dependent relationship between cannabinoid exposure and symptom severity, though individual susceptibility factors and the specific cannabinoid profile of products (THC concentration, presence of CBD, terpenes) likely play important confounding roles. Healthcare providers should maintain clinical suspicion for CHS in patients presenting with intractable nausea and vomiting, especially those reporting frequent or high-dose cannabis use, as the condition is frequently misdiagnosed and may lead to unnecessary investigations and treatments. Practically, screening for cannabis use patterns—including frequency, potency, and consumption method—should become routine in patients with refractory n
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: